RxDoctor Payments Data

Semone West, MD

Child & Adolescent Psychiatry · Lemont, ILNPI 1750475109

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 57 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Johnson & Johnson at 33.6% of the total. Reporting peaked in 2019 at $408 and has fallen 65.4% since, to $141 in 2024.

$1,079in general payments, 2019–2025

Across 57 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$362
  • Otsuka America Pharmaceutical, Inc.$175
  • Sunovion Pharmaceuticals Inc.$81
  • Neurocrine Biosciences, Inc.$56
  • Lundbeck LLC$51
  • Tris Pharma Inc$44
  • plus $309 from 12 others

What the payments were for

  • Food & beverage$1,079100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,079 in reported general payments places this provider in the 75th percentile of 124 child & adolescent psychiatry providers in Illinois.

See all child & adolescent psychiatry providers in Illinois

Medicare billing

Part B allowed, 2024
$41,140
Medicare patients
67
Services billed
355

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate11$27,387
VraylarCariprazine Hcl12$20,469
Paliperidone ErPaliperidone11$2,387
Gabapentin27$814
Lorazepam29$590
Trazodone Hcl20$508
Paroxetine Hcl17$488
Divalproex Sodium12$398
Aripiprazole16$385
Bupropion XlBupropion Hcl15$344
Quetiapine Fumarate16$313
Alprazolam20$253
Lamotrigine13$231
Buspirone Hcl14$208
Sertraline Hcl17$114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$362$27,38711 claims
AbbVieVraylar$30$20,46912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 124 child & adolescent psychiatry providers in Illinois.

Other child & adolescent psychiatry in Lemont

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →